Peter Weber et al.
Epilepsy & behavior : E&B, 24(1), 138-140 (2012-04-17)
We report the case of an adolescent girl who suffered from symptomatic refractory focal epilepsy after an arteria cerebri media insult 15 years prior to this report. Five weeks after initiation of an add-on therapy with vigabatrin, she was seizure...
The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
Lisa M Clayton et al.
Ophthalmology, 119(10), 2152-2160 (2012-08-03)
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL). Cross-sectional observational study....
O Heinzlef et al.
Revue neurologique, 168 Suppl 3, S62-S68 (2012-06-29)
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do...
M Iu Dorofeeva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(6 Pt 2), 27-31 (2012-09-18)
Tuberous sclerosis complex is a multisystem genetic disorder. Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time. Onset usually occurs during childhood and up to one third of children with tuberous sclerosis...